Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers by developing breakthrough T cell immunotherapies with improved safety and efficacy. Our highly innovative platform, COBRA™, is the most advanced bispecific T cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.
Founded in 2016, Maverick Therapeutics is led by a team of leading experts in protein engineering and T cell therapeutic research and development. Our team is composed of a group of individuals with incredibly diverse backgrounds bound together by a common passion to develop safe and efficacious treatments for a broad number of patients with solid tumor cancers. Each individual brings their own distinct personality and specialized experience to the table to form an integrated discovery and development team. Our approach is to focus foremost on what the patient population needs, and then reverse engineer the technology that can provide that solution.
In early 2017, Maverick announced $125 million of committed funding from Takeda Pharmaceuticals (“Takeda”), MPM BioVentures 2014 and MPM Capital’s UBS Oncology Impact Fund. Based on the promise of the Company’s early-stage research, we entered into a five-year drug development project with Takeda.